[Combination chemotherapy for acute myeloid leukemia].

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Combination chemotherapy with cytarabine (Ara-C) and anthracyclines is a cornerstone therapy for acute myeloid leukemia (AML), yielding significant complete remission (CR) rates.
• Established salvage therapies exist for relapsed or refractory AML.
• Ongoing trials explore novel combinations, such as chemotherapy with gemtuzumab ozogamicin, for poor-risk AML.

Purpose of the Study:

• To highlight the need for novel therapeutic strategies in AML treatment.
• To emphasize the importance of developing new approaches beyond conventional chemotherapy.
• To underscore the potential of combining conventional drugs with molecularly targeted agents and therapies targeting leukemia stem cells.

Main Methods:

• Review of current standard and salvage therapies for AML.
• Discussion of ongoing clinical trials involving novel drug combinations.
• Conceptual exploration of future therapeutic strategies.

Main Results:

• Current combination chemotherapy achieves high CR rates but cure rates require improvement.
• Salvage therapies provide options for relapsed/refractory cases.
• Novel approaches are under investigation to enhance treatment efficacy.

Conclusions:

• Improving AML cure rates necessitates the development of innovative therapeutic strategies.
• Combining conventional anti-leukemia drugs with molecule-targeting reagents may increase CR and cure rates.
• Targeting leukemia stem cells is crucial for increasing the overall cure rate of AML.